Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure is seeing strong growth in all three of its commercial products, mainly driven by the success of its Optune Gio device in treating solid tumor cancers. The company's recent updates, such as receiving CE Mark for Optune Pax in locally advanced pancreatic cancer and adding TTFields as a recommended treatment for brain metastases, further supports the potential of its products. While the TRIDENT trial did not meet its primary endpoint, the company's core product, Optune Gio, remains the standard of care for GBM, and any impact on the company's valuation is minimal. The success of its recent launches and upcoming regulatory and clinical catalysts make NovoCure an attractive investment opportunity for potential growth in the oncology market.

Bears say

NovoCure is a company with a strong focus on oncology, particularly in the development and commercialization of Tumor Treating Fields (TTFields) devices for the treatment of solid tumor cancers. While the company has reported a strong quarter with lower operating expenses and anticipates approval for TTFields therapy for brain metastases from NSCLC in Q4 2026, there are potential risks to achieving the increased price target of $52. These risks include safety concerns emerging, lower than expected efficacy from clinical programs, commercial competition, regulatory hurdles, and potential issues with intellectual property protection.

Novocure (NVCR) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 5 analysts, Novocure (NVCR) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.